Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial (Q33403800)

26 July 2017

title

Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

0 references

1 reference

Patrick A Ott

1

1 reference

26 July 2017

Jason Chang

2

1 reference

26 July 2017

Kathleen Madden

3

1 reference

26 July 2017

Rajni Kannan

4

1 reference

26 July 2017

Caroline Muren

5

1 reference

26 July 2017

Crystal Escano

6

1 reference

26 July 2017

Xin Cheng

7

1 reference

26 July 2017

Yongzhao Shao

8

1 reference

26 July 2017

Sandra Mendoza

9

1 reference

26 July 2017

Alex Gandhi

10

1 reference

26 July 2017

Leonard Liebes

11

1 reference

26 July 2017

Anna C Pavlick

12

1 reference

26 July 2017

publication date

12 October 2012

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

71

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

183-191

1 reference

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Emerging Bcl-2 inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Apoptosis and melanoma chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

The role of Bcl-2 family members in the progression of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1995-7

10.1007/S00280-012-1995-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1009518010

0 references

1 reference